The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer

Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin

Changes in neutrophile-to-lymphocyte ratio as predictive and

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and

Taking a Closer Look at Recurrent/Metastatic SCCHN - ppt download

Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin

A randomized phase III study of fractionated docetaxel

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary

Cetuximab, fluorouracil and cisplatin with or without docetaxel

Induction chemotherapy with lobaplatin and fluorouracil versus

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in

Avelumab as neoadjuvant therapy in patients with urothelial non

Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin